Ron J Mandel,
Professor
Department:
Department of Neuroscience
Business Phone:
(352) 294-5547
Business Email:
rmandel@ufl.edu
About Ron J Mandel
My research has focused on gene transfer to the nervous system both to treat animal models of neurological disorders and to model neurological disorders. The bulk of my research has focused on Parkinson’s disease. During my second stint at Wallenberg Neuroscience Center, we developed and validated the nigral rAAV-α-synuclein model of Parkinson’s disease. In collaboration with Nicholas Muzyczka, we have continued to use rAAV vectors to study the basic biology of α-synuclein in substantia nigra both by studying various forms of α-synuclein and by knocking down α-synuclein via shRNAs. I have done the most work on rAAV mediated GDNF delivery for the treatment of PD. More recently, I have branched out to gene therapy for many neurological disorders. Currently, I am using rAAV delivered DREADDs to study the basal ganglia circuits involved in repetitive behaviors which may be related to autism.
Teaching Profile
Courses Taught
2016-2024
GMS6705 Functional Human Neuroanatomy
2020-2024
GMS7795 Special Topics in Neuroscience
2016-2025
GMS6750 Molecular Pathobiology of Neural Disease
2010-2013,2015-2022,2018-2024,2022-2024
GMS6029 Brain Journal Club
2019-2024
DEN5120C Physiology
2018-2019,2021-2025
BMS6020 Clinical Neuroscience
2018
MDT7801 Elect Top/Neuroscienc
2018
GMS7980 Research for Doctoral Dissertation
2018
GMS7979 Advanced Research
2015
VEM5110 Animal Systems 1
2010
IDH4917 Undergrad Research
2006-2007
GMS7794 Neuroscience Seminar
2022-2025
GMS6713 Neurobiol of Behav Disorders
2022-2025
GMS6701 Functional and Comparative Neuroanatomy for Professionals
2024
GMS6910 Supervised Research
2024-2025
GMS6757 Introduction to Alzheimer’s Disease and Related Dementias: Clinical and Mechanistic Principles
2024-2025
GMS6022 Principles of Neurophysiology
Publications
Academic Articles
2023
Correction: Site-specific modifications to AAV8 capsid yields enhanced brain transduction in the neonatal MPS IIIB mouse.
Gene therapy.
30(9)
[DOI] 10.1038/s41434-023-00412-2.
[PMID] 37495717.
2021
A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system.
Molecular therapy : the journal of the American Society of Gene Therapy.
29(9):2806-2820
[DOI] 10.1016/j.ymthe.2021.07.010.
[PMID] 34298128.
2021
Site-specific modifications to AAV8 capsid yields enhanced brain transduction in the neonatal MPS IIIB mouse.
Gene therapy.
28(7-8):447-455
[DOI] 10.1038/s41434-020-00206-w.
[PMID] 33244179.
2020
Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson’s disease.
Experimental neurology.
325
[DOI] 10.1016/j.expneurol.2019.113159.
[PMID] 31843492.
2020
The Future of GDNF in Parkinson’s Disease.
Frontiers in aging neuroscience.
12
[DOI] 10.3389/fnagi.2020.593572.
[PMID] 33364933.
2017
Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates.
Acta neuropathologica communications.
5(1)
[DOI] 10.1186/s40478-017-0451-7.
[PMID] 28619074.
2016
Type 3 Adenylyl Cyclase and Somatostatin Receptor 3 Expression Persists in Aged Rat Neocortical and Hippocampal Neuronal Cilia.
Frontiers in aging neuroscience.
8
[DOI] 10.3389/fnagi.2016.00127.
[PMID] 27303293.
2014
Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.
Gene therapy.
21(7):682-93
[DOI] 10.1038/gt.2014.42.
[PMID] 24807806.
2014
Selective Knockout of Acid Alpha-Glucosidase Gaa Gene Expression in the Medulla Alters Breathing
The FASEB's Journal.
28(1, S)
2013
Raav2/5-Mediated Gene Transfer Is Less Efficient in the Aged Rat Brain: Examination of Alpha-Synuclein-Mediated Neurodegeneration in the Nigrostriatal System
Cell Transplantation.
22
2013
Viral Vector Mediated Overexpression of Pleiotrophin for Disease Modification in Parkinson’s Disease
Molecular Therapy.
21:S146-S147
2012
Alpha-Synuclein Overexpression in the Aged Brain: Is the Aging Nigrostriatal System More Susceptible To Alpha-Synuclein-Mediated Neurodegeneration?
Cell Transplantation.
21(4):779-780
2012
Alpha-Synuclein Overexpression in the Aged Rat Brain: Is the Aging Nigrostriatal System More Suseptible To Alpha-Synuclein Mediated Neurodegeneration?
Molecular Therapy.
20
2012
Effects of Minozak And/Or Genistein On the Central Nervous System of Sanfilippo Syndrome Type B Mice
Molecular Genetics and Metabolism.
105(2)
[DOI] 10.1016/j.ymgme.2011.11.060.
2012
Regulated protein expression for in vivo gene therapy for neurological disorders: progress, strategies, and issues.
Neurobiology of disease.
48(2):212-21
[DOI] 10.1016/j.nbd.2012.03.001.
[PMID] 22426391.
2012
Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model.
Molecular therapy : the journal of the American Society of Gene Therapy.
20(3):544-54
[DOI] 10.1038/mt.2011.216.
[PMID] 22008908.
2011
AAV6-mediated gene silencing fALS short.
Molecular therapy : the journal of the American Society of Gene Therapy.
19(2):231-3
[DOI] 10.1038/mt.2010.306.
[PMID] 21289637.
2011
Effects of Oxyten in An Invertebrate Model of Amphetamine Neurotoxicity
Biological Psychiatry.
69
2011
Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington’s disease with 140 CAG repeats.
Experimental neurology.
228(2):173-82
[DOI] 10.1016/j.expneurol.2010.12.017.
[PMID] 21192926.
2011
Raav-Mediated Shrna Knockdown of Alpha-Synuclein in the Rat Substantia Nigra Results in Aberrant Dopamine Handling
Cell Transplantation.
20
2011
The development of flexible lentiviral vectors for gene transfer in the CNS.
Experimental neurology.
229(2):201-6
[DOI] 10.1016/j.expneurol.2011.03.013.
[PMID] 21459087.
2011
Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.
Human molecular genetics.
20(14):2770-82
[DOI] 10.1093/hmg/ddr176.
[PMID] 21515588.
2010
A Behavioral, Histopatholgical, and Anatomical Characterization of the Cag140 Huntington’s Disease Mouse Model
Cell Transplantation.
19
2010
Cere-110, An Adeno-Associated Virus-Based Gene Delivery Vector Expressing Human Nerve Growth Factor for the Treatment of Alzheimer’s Disease
Current Opinion in Molecular Therapeutics.
12:240-247
2010
CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer’s disease.
Current opinion in molecular therapeutics.
12(2):240-7
[PMID] 20373268.
2010
Development of gene therapy for neurological disorders.
Discovery medicine.
9(46):204-11
[PMID] 20350486.
2010
Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates.
Molecular therapy : the journal of the American Society of Gene Therapy.
18(3):579-87
[DOI] 10.1038/mt.2009.216.
[PMID] 19773746.
2010
Enhanced Cns Transgene Expression By Raav Capsid Tyrosine Mutants
Cell Transplantation.
19
2010
In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration.
Molecular therapy : the journal of the American Society of Gene Therapy.
18(8):1450-7
[DOI] 10.1038/mt.2010.115.
[PMID] 20551914.
2010
Optimal Nigrostriatal Transduction Targets for Pleiotrophin Gene Therapy in the Parkinsonian Rodent Model
Cell Transplantation.
19
2010
α-Synuclein expression in rat substantia nigra suppresses phospholipase D2 toxicity and nigral neurodegeneration.
Molecular therapy : the journal of the American Society of Gene Therapy.
18(10):1758-68
[DOI] 10.1038/mt.2010.137.
[PMID] 20664530.
2009
AAV9: a potential blood-brain barrier buster.
Molecular therapy : the journal of the American Society of Gene Therapy.
17(3):403-5
[DOI] 10.1038/mt.2009.15.
[PMID] 19247366.
2009
Absolute Control of Raav Mediated Gdnf Expression in the Nigrostriatal Tract Using a Single Vector Tetracycline Responsive Expression System
Molecular Therapy.
17
2009
Bilateral Nigral Raav5-Mediated Gdnf Over-Expression Activates Crh Neurons in the Paraventricular Nucleus of the Hypothalamus and Induces Robust Weight Loss in Obese Leptin-Resistant Rats
Molecular Therapy.
17
2009
Determination of Peak Developmental Levels of Pleiotrophin for Optimized Gene Transfer Therapy in Parkinsonian Animal Models
Cell Transplantation.
18
2009
Differential Infectivity Following Basal Ganglia Administration of Differing Aav Serotypes in Nonhuman Primates
Cell Transplantation.
18:212-213
2009
Gene Therapy for Neurological Disorders: Challenges and Future Prospects for the Use of Growth Factors for the Treatment of Parkinson’s Disease
.
9:375-388
2009
Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson’s disease.
Current gene therapy.
9(5):375-88
[PMID] 19860652.
2009
Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity.
Molecular therapy : the journal of the American Society of Gene Therapy.
17(6):980-91
[DOI] 10.1038/mt.2009.45.
[PMID] 19277011.
2009
Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats.
Journal of neurochemistry.
111(2):355-67
[DOI] 10.1111/j.1471-4159.2009.06340.x.
[PMID] 19686242.
2009
Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
29(5):1544-53
[DOI] 10.1523/JNEUROSCI.4491-08.2009.
[PMID] 19193901.
2009
Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.
Molecular therapy : the journal of the American Society of Gene Therapy.
17(3):524-37
[DOI] 10.1038/mt.2008.284.
[PMID] 19142181.
2009
Tight Durable Long-Term Doxycycline-Mediated Gdnf Regulation From a Single Raav Vector in the Nigrostiatal Tract
Cell Transplantation.
18:224-225
2009
Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector.
Molecular therapy : the journal of the American Society of Gene Therapy.
17(11):1857-67
[DOI] 10.1038/mt.2009.196.
[PMID] 19707186.
2009
Weight Loss in Obese Leptin-Resistant Rats Induced By Activation of Crh Neurons in the Paraventricular Nucleus of the Hypothalamus By Overexpression of Substantial Nigral-Injected Raav5-Gdnf
Cell Transplantation.
18
2008
Effects of Raav Delivered Heat Shock Protein 27 and 70 To the Striatum of a Knock-in Mouse Model of Huntington’S Disease
Cell Transplantation.
17
2008
Genome-wide analysis of aging and learning-related genes in the hippocampal dentate gyrus.
Neurobiology of learning and memory.
89(4):379-96
[DOI] 10.1016/j.nlm.2007.11.006.
[PMID] 18234529.
2008
Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons.
Human gene therapy.
19(1):61-70
[PMID] 18052722.
2008
Recombinant adeno-associated virus-mediated global anterograde delivery of glial cell line-derived neurotrophic factor to the spinal cord: comparison of rubrospinal and corticospinal tracts in the rat.
Human gene therapy.
19(1):71-82
[PMID] 18072858.
2008
Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
Journal of neuroscience research.
86(8):1748-57
[DOI] 10.1002/jnr.21636.
[PMID] 18293418.
2008
The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.
Proceedings of the National Academy of Sciences of the United States of America.
105(2):763-8
[DOI] 10.1073/pnas.0711053105.
[PMID] 18178617.
2008
The Potential for the Trophic Factor Pleiotrophin (Ptn) To Protect the Parkinsonian Brain
Cell Transplantation.
17
2008
Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo.
Neurobiology of disease.
29(3):446-55
[DOI] 10.1016/j.nbd.2007.11.003.
[PMID] 18166484.
2008
Viral vectors for in vivo gene transfer in Parkinson’s disease: properties and clinical grade production.
Experimental neurology.
209(1):58-71
[PMID] 17916354.
2007
BDNF tagging polymorphisms and haplotype analysis in sporadic Parkinson’s disease in diverse ethnic groups.
Neuroscience letters.
415(1):59-63
[PMID] 17229524.
2007
Changes in transcription within the CA1 field of the hippocampus are associated with age-related spatial learning impairments.
Neurobiology of learning and memory.
87(1):21-41
[PMID] 16829144.
2007
Comprehensive screening of a North American Parkinson’s disease cohort for LRRK2 mutation.
Neuro-degenerative diseases.
4(5):386-91
[PMID] 17622782.
2007
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions.
Current gene therapy.
7(5):347-60
[PMID] 17979681.
2007
Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
Brain : a journal of neurology.
130(Pt 3):799-815
[PMID] 17303591.
2007
rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson’s disease.
Experimental neurology.
207(2):289-301
[PMID] 17678648.
2007
Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat.
Molecular therapy : the journal of the American Society of Gene Therapy.
15(8):1504-11
[PMID] 17565350.
2006
A method for a more complete in vitro Parkinson’s model: slice culture bioassay for modeling maintenance and repair of the nigrostriatal circuit.
Journal of neuroscience methods.
157(1):1-9
[PMID] 16704878.
2006
Genome-wide genotyping in Parkinson’s disease and neurologically normal controls: first stage analysis and public release of data.
The Lancet. Neurology.
5(11):911-6
[PMID] 17052657.
2006
Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity.
Neurobiology of aging.
27(3):459-70
[PMID] 15964099.
2006
LRRK2 mutations in a clinic-based cohort of Parkinson’s disease.
European journal of neurology.
13(12):1298-301
[PMID] 17116211.
2006
Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders.
Molecular therapy : the journal of the American Society of Gene Therapy.
13(3):463-83
[PMID] 16412695.
2006
RNA knockdown as a potential therapeutic strategy in Parkinson’s disease.
Gene therapy.
13(6):517-24
[PMID] 16267570.
2006
The human prion gene M129V polymorphism is not associated with idiopathic Parkinson’s disease in three distinct populations.
Neuroscience letters.
395(3):227-9
[PMID] 16298483.
2005
Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson’s disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
25(4):769-77
[PMID] 15673656.
2005
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington’s disease transgenic mice.
Molecular therapy : the journal of the American Society of Gene Therapy.
12(4):618-33
[PMID] 16019264.
2005
Recombinant adeno-associated viral vectors in the nervous system.
Human gene therapy.
16(7):781-91
[PMID] 16000060.
2005
Reversal of dyskinesias in an animal model of Parkinson’s disease by continuous L-DOPA delivery using rAAV vectors.
Brain : a journal of neurology.
128(Pt 3):559-69
[PMID] 15659429.
2005
Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion.
Molecular therapy : the journal of the American Society of Gene Therapy.
11(2):327-31
[PMID] 15668145.
2005
Voluntary exercise delays monogenetic obesity and overcomes reproductive dysfunction of the melanocortin-4 receptor knockout mouse.
Biochemical and biophysical research communications.
326(3):638-44
[PMID] 15596147.
2004
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease.
Archives of neurology.
61(12):1898-904
[PMID] 15596610.
2004
Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain.
Journal of virology.
78(12):6344-59
[PMID] 15163728.
2004
Clinical trials in neurological disorders using AAV vectors: promises and challenges.
Current opinion in molecular therapeutics.
6(5):482-90
[PMID] 15537049.
2004
Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system.
Molecular therapy : the journal of the American Society of Gene Therapy.
10(2):302-17
[PMID] 15294177.
2003
Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Molecular therapy : the journal of the American Society of Gene Therapy.
7(5 Pt 1):580-7
[PMID] 12718900.
2003
Anterograde delivery of brain-derived neurotrophic factor to striatum via nigral transduction of recombinant adeno-associated virus increases neuronal death but promotes neurogenic response following stroke.
The European journal of neuroscience.
17(12):2667-78
[PMID] 12823474.
2003
Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats.
Neurobiology of disease.
14(3):542-56
[PMID] 14678770.
2003
Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson’s disease.
Proceedings of the National Academy of Sciences of the United States of America.
100(5):2884-9
[PMID] 12601150.
2003
Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus).
Experimental neurology.
184(1):536-48
[PMID] 14637123.
2002
Gene therapy for pyruvate dehydrogenase E1alpha deficiency using recombinant adeno-associated virus 2 (rAAV2) vectors.
Molecular therapy : the journal of the American Society of Gene Therapy.
6(3):394-9
[PMID] 12231176.
2002
Neuropathological and behavioral consequences of adeno-associated viral vector-mediated continuous intrastriatal neurotrophin delivery in a focal ischemia model in rats.
Neurobiology of disease.
9(2):187-204
[PMID] 11895371.
2002
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
22(7):2780-91
[PMID] 11923443.
2002
Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.
Proceedings of the National Academy of Sciences of the United States of America.
99(7):4708-13
[PMID] 11917105.
2002
Suppression of insult-induced neurogenesis in adult rat brain by brain-derived neurotrophic factor.
Experimental neurology.
177(1):1-8
[PMID] 12429205.
2000
Adeno-associated virus vector-mediated gene transfer to somatic cells in the central nervous system.
Advances in virus research.
55:507-28
[PMID] 11050954.
2000
Age-related decreases in GTP-cyclohydrolase-I immunoreactive neurons in the monkey and human substantia nigra.
The Journal of comparative neurology.
426(4):534-48
[PMID] 11027397.
2000
Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson’s disease.
Experimental neurology.
161(1):212-9
[PMID] 10683287.
2000
Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
20(12):4686-700
[PMID] 10844038.
2000
The use of a recombinant lentiviral vector for ex vivo gene transfer into the rat CNS.
Neuroreport.
11(18):3973-7
[PMID] 11192612.
2000
Towards a neuroprotective gene therapy for Parkinson’s disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Brain research.
886(1-2):82-98
[PMID] 11119690.
1999
Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson’s disease.
Neuroscience.
92(1):185-96
[PMID] 10392841.
1999
Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration.
Experimental neurology.
155(1):59-64
[PMID] 9918705.
1999
Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson’s disease using recombinant adeno-associated viral vectors.
Experimental neurology.
159(1):47-64
[PMID] 10486174.
1999
Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson’s disease.
Experimental neurology.
160(1):205-14
[PMID] 10630205.
1999
Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice.
Neuron.
22(1):167-78
[PMID] 10027299.
1998
A third-generation lentivirus vector with a conditional packaging system.
Journal of virology.
72(11):8463-71
[PMID] 9765382.
1998
Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson’s disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
18(11):4271-84
[PMID] 9592104.
1998
In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase.
Experimental neurology.
151(2):249-64
[PMID] 9628761.
1998
Regulation of gene expression in vivo following transduction by two separate rAAV vectors.
Nature biotechnology.
16(8):757-61
[PMID] 9702775.
1998
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.
Journal of virology.
72(12):9873-80
[PMID] 9811723.
1997
Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in rats.
Proceedings of the National Academy of Sciences of the United States of America.
94(25):14083-8
[PMID] 9391156.
1997
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo.
Nature biotechnology.
15(9):871-5
[PMID] 9306402.
1997
Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson’s disease.
Experimental neurology.
144(1):147-56
[PMID] 9126164.
1996
Amphiregulin in lung branching morphogenesis: interaction with heparan sulfate proteoglycan modulates cell proliferation.
Development (Cambridge, England).
122(6):1759-67
[PMID] 8674415.
1995
Amphetamine sensitivity in open-field activity vs. the prepulse inhibition paradigm.
Brain research bulletin.
37(2):219-22
[PMID] 7606498.
1994
Amphetamine induces excess release of striatal acetylcholine in vivo that is independent of nigrostriatal dopamine.
Brain research.
653(1-2):57-65
[PMID] 7982076.
1993
A quantitative estimate of the role of striatal D-2 receptor proliferation in dopaminergic behavioral supersensitivity: the contribution of mesolimbic dopamine to the magnitude of 6-OHDA lesion-induced agonist sensitivity in the rat.
Behavioural brain research.
59(1-2):53-64
[PMID] 8155293.
1993
Characterization of GABA release from intrastriatal striatal transplants: dependence on host-derived afferents.
Neuroscience.
53(2):403-15
[PMID] 8098510.
1993
Trophism, transplantation, and animal models of Parkinson’s disease.
Experimental neurology.
124(1):140-9
[PMID] 8282071.
1992
Behavioral quantification of striatal dopaminergic supersensitivity after bilateral 6-hydroxydopamine lesions in the mouse.
Pharmacology, biochemistry, and behavior.
41(2):343-7
[PMID] 1574523.
1992
Dopaminergic transplants normalize amphetamine- and apomorphine-induced Fos expression in the 6-hydroxydopamine-lesioned striatum.
Neuroscience.
46(4):943-57
[PMID] 1347413.
1992
Fos expression in intrastriatal striatal grafts: regulation by host dopaminergic afferents.
Brain research.
583(1-2):207-15
[PMID] 1504828.
1992
Independent effects of age and nucleus basalis magnocellularis lesion: maze learning, cortical neurochemistry, and morphometry.
Behavioral neuroscience.
106(5):776-88
[PMID] 1280146.
1992
Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat.
Brain research.
581(2):217-28
[PMID] 1393530.
1990
Behavioral demonstration of a reciprocal interaction between dopamine receptor subtypes in the mouse striatum: possible involvement of the striato-nigral pathway.
Brain research bulletin.
25(2):285-92
[PMID] 2146002.
1990
Bromocriptine-induced rotation: characterization using a striatal efferent lesion in the mouse.
Brain research bulletin.
24(2):175-80
[PMID] 2108786.
1990
Nucleus basalis lesions fail to induce senile plaques in the rat.
Experimental neurology.
108(1):88-90
[PMID] 2318291.
1990
Tetrahydroaminoacridine improves the spatial acquisition deficit produced by nucleus basalis lesions in rats.
Experimental neurology.
108(3):221-8
[PMID] 2351210.
1990
The Importance of Graft Placement and Task Complexity for Transplant-Induced Recovery of Simple and Complex Sensorimotor Deficits in Dopamine Denervated Rats.
The European journal of neuroscience.
2(10):888-894
[PMID] 12106096.
1989
Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers.
The Journal of pharmacology and experimental therapeutics.
251(2):612-9
[PMID] 2810114.
1989
Enhanced detection of nucleus basalis magnocellularis lesion-induced spatial learning deficit in rats by modification of training regimen.
Behavioural brain research.
31(3):221-9
[PMID] 2914073.
1989
Multisite recording of brain field potentials and unit activity in freely moving rats.
Journal of neuroscience methods.
28(3):209-17
[PMID] 2755179.
1989
Spatial learning in rats: correlation with cortical choline acetyltransferase and improvement with NGF following NBM damage.
Experimental neurology.
104(3):208-17
[PMID] 2721623.
1988
Nucleus basalis and thalamic control of neocortical activity in the freely moving rat.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
8(11):4007-26
[PMID] 3183710.
1988
Physostigmine improves water maze performance following nucleus basalis magnocellularis lesions in rats.
Psychopharmacology.
96(3):421-5
[PMID] 3146779.
1987
Alteration of calmodulin distribution does not accompany dopaminergic supersensitization of the mouse striatum.
Journal of neuroscience research.
17(3):247-50
[PMID] 3037094.
1985
Quantification of lesion-induced dopaminergic supersensitivity using the rotational model in the mouse.
Brain research.
330(2):358-63
[PMID] 3921193.
1974
Thermal denaturation of DNA and DNA:polypeptide complexes. Simultaneous absorption and circular dichroism measurements.
Biochemical and biophysical research communications.
59(2):672-9
[PMID] 4859561.
Grants
Jul 2020
– Jul 2023
OR-DRPD-ROF2020:Role of the Hyperdirect Basal Ganglia Pathway in Mediating Repetitive, Inflexible Behavior
Role: Co-Investigator
Funding: UF RESEARCH
Aug 2017
– Nov 2023
Optimizing AAV Vectors for Central Nervous System transduction
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Sep 2016
– Jul 2022
Functional mapping of peripheral and central circuits for airway protection and breathing
Role: Co-Investigator
Funding: NATL INST OF HLTH OD
May 2013
– Dec 2017
Development of appropriate control transgenes for long term viral vector mediated gene transfer and optical imaging in the Nigra
Role: Principal Investigator
Funding: FOX FOU, MICHAEL J
Contact Details
Phones:
- Business:
- (352) 294-5547
Emails:
- Business:
- rmandel@ufl.edu
Addresses:
- Business Street:
-
PO BOX 100244
Department of Neuroscience
Gainesville FL 32610